Day: February 12, 2025

VANCOUVER, British Columbia, Feb. 11, 2025 (GLOBE NEWSWIRE) — Zacatecas Silver Corp. (“Zacatecas Silver” or the “Company,” ZAC: TSX Venture; ZCTSF: OTC Markets; 7TV: Frankfurt) is pleased to announce that it has designed a drill program to follow up on previous work at its silver projects located in Zacatecas, Mexico. The Company will now seek bids from drill contractors based on the proposed program. The drilling plan aims to expand the current resource (see News Release dated May 30, 2023, for details) and follow up on previously drilled high-grade intercepts outside the known resource area. Drilling by the Company and previous operators has identified two significant vein systems warranting further exploration and drilling:Panuco Deposit: Extensive drilling and trench work at Panuco have returned high-grade silver results,...

Company’s European Business to Continue OAKLAND, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) — Getaround, Inc. (“Getaround” or the “Company”), a global car-sharing marketplace, announced today that it has plans to commence an orderly wind-down of its U.S. business operations, which includes its car-share and HyreCar businesses. Getaround’s European business will continue operating to provide car-sharing services for customers in all current European markets. “This has been an incredibly difficult decision, one that was not made lightly and only after careful consideration of various strategic options,” said AJ Lee, Interim CEO and COO. “Despite significant improvements in overall profitability and extensive restructuring efforts, the Company has faced an ongoing lack of liquidity which has made U.S. operations no longer...

GOMEKLI™ (mirdametinib) capsules and tablets for oral suspensionGOMEKLI™ (mirdametinib) capsules and tablets for oral suspensionSaqib Islam, SpringWorks Therapeutics CEOSaqib Islam, SpringWorks Therapeutics CEOSpringWorks Therapeutics, IncSpringWorks Therapeutics, Inc.GOMEKLI™ (mirdametinib) logoGOMEKLI™ (mirdametinib) logo– GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on positive data from Phase 2b ReNeu trial, which showed GOMEKLI treatment resulted in robust ORR, deep and durable reductions in tumor volume, and a manageable safety profile – – SpringWorks granted rare pediatric disease priority review voucher by the FDA – Photos accompanying this announcement are available at:  https://www.globenewswire.com/NewsRoom/AttachmentNg/8eb8effc-49a5-4b24-911f-d3e6dfa9c8a9https://www.globenewswire.com/NewsRoom/AttachmentNg/f1041678-3f79-43b7-a101-2390fb8cb86bhttps://www.globenewswire.com/NewsRoom/AttachmentNg/7d8cb318-e5f8-4944-8736-24cb19a5dec9https://www.globenewswire.com/NewsRoom/AttachmentNg/072d748b-3237-48ad-8d83-1c6c23dda65f STAMFORD,...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Feb. 11, 2025 (GLOBE NEWSWIRE) — Prairie Provident Resources Inc. (TSX:PPR) (“Prairie Provident” or the “Company”) is pleased to announce that it has entered into an agreement with Research Capital Corporation, as lead agent and sole bookrunner, on behalf of a syndicate of agents including Haywood Securities Inc. (collectively, the “Agents”), for a brokered “best efforts” equity financing for aggregate gross proceeds of up to approximately $9,100,000, comprised of: (a) an offering up to 96,470,589 units of the Company (“Units”) at a price of $0.0425 per Unit for gross proceeds of up to $4,100,000, on a prospectus-exempt basis pursuant to the ‘listed issuer financing exemption’ (LIFE) under applicable Canadian securities laws...